Prefilled drug delivery system developer Vetter and medical device maker Microdermics said yesterday that the companies are working to develop a novel microneedle drug delivery system. Microdermics has developed a low-cost, commercially scalable, customizable microneedle platform that delivers vaccines and biologics. The company said it expects its intradermal delivery system will enter Phase I clinical trials this […]
Research & Development
Chiltern acquires Integrated Development Associates
Contract research organization Chiltern announced today that it is expanding its Japanese and Asian presence through its purchase of Integrated Development Associates. Financial terms of the deal were not disclosed. IDA has staff in Japan, Korea and Southeast Asia – and offers opportunities to integrate the region into global drug development, according to Chiltern. IDA’s expertise includes […]
X-Biotix to address antibiotic resistance with chemical scaffolds
X-Biotix Therapeutics launched today with technology from Harvard Medical School that the company said will aim to address the threat of antibiotic resistance. According to the multi-year collaboration and license agreement, the team plans to identify antibiotic scaffolds that target multi-drug-resistant Gram-negative pathogens. X-Biotix spun out of the privately-held biotech X-Chem, which develops novel small molecule therapeutics […]
Revive Therapeutics, University of Wisconsin-Madison ink deal for cannabinoid drug delivery tech
Revive Therapeutics (OTC:RVVTF) said today that it inked a research agreement with the University of Wisconsin-Madison to develop a drug delivery technology for cannibinoids. The research program, led by Jess Reed, is slated to evaluate chitosan-tannin composite biomaterial as a delivery mechanism for cannabinoids. Therapeutic biomaterials made from a composite of chitosan and tannin include […]
Medtech stories we missed this week: May 26, 2017
From Merck’s new licensing agreement to surgical study data being touted, here are medtech stories we missed this week but thought were still worth mentioning. 1. Merck inks exclusive licensing agreement for Alzheimer’s antibody Merck announced in a May 25 press release that it has entered an exclusive worldwide license agreement with Teijin Pharma. The […]
Senseonics prices $41m underwritten offering for Eversense CGM
Senseonics (NYSE:SENS) said today that it priced an underwritten offering of 29 million shares of common stock at $1.41 apiece to a group of institutional investors. Roche (PINK:RHHBY) agreed to purchase 21 million shares and New Enterprise Associates agreed to purchase 7 million shares in the offering, according to the Germantown, Md.-based company. Senseonics said […]
Study: Radiation may boost immunotherapy in mesothelioma treatment
Doctors in Pennsylvania reported this week that combining immunotherapy drugs with radiotherapy could help to more efficiently treat malignant pleural mesothelioma. The analysis from the University of Pennsylvania looked at studies that combined immunotherapy drugs like Merck‘s (NYSE:MRK) Keytruda with radiation therapy. The team concluded that radiotherapy may boost the cancer-killing effects of immunotherapies. Malignant pleural […]
9 diabetes breakthroughs you need to know
Diabetes is a disease that affects the body’s ability to produce and respond to insulin. About 29.1 million people have diabetes in the U.S, according to the Centers for Disease Control and Prevention. Of that number, 8.1 million go undiagnosed. One of the most popular breakthroughs in diabetes research has been the artificial pancreas, which […]
Liquidia touts Phase I data for sustained-release post-surgical pain reliever
Liquidia Technologies touted initial data from its LIQ865 Phase I trial, which evaluated its sustained-delivery formulation of bupivacaine for post-surgical pain relief. The trial was the 1st evaluation of the company’s formulation in humans. Researchers assessed the safety, pharmacokinetic profile and pharmacodynamic response of a single-ascending dose in healthy adult males. Initial data showed that […]
Harvard Apparatus touts pump for brain injections
Harvard Apparatus is boasting of the abilities of its Pump 11 Elite Nanomite – a single syringe infusion/withdrawal programmable syringe pump designed for precise point infusion applications. Researchers used the Pump 11 Elite Nanomite to successfully perform injections into specific sub-regions of the caudate nucleus in the brain. They repeatedly injected a 1 mm diameter target in […]
